Eris Lifesciences Fined ₹1.3 Lakh by BSE & NSE for Director Compliance Lapse
Eris Lifesciences Limited was fined ₹65,000 each by BSE and NSE on February 27, 2026, totaling ₹1.3 lakh. The penalty stems from non-compliance related to an Independent Director's term completion. The company is in the process of appointing a new director to address the board composition issue.
The financial impact is minimal, limited to the penalty amount of ₹1.3 lakh, and the company expects to resolve the compliance issue soon.
The company has been fined by stock exchanges for non-compliance, which is a negative event.
Eris Lifesciences Limited has been fined a total of ₹1.3 lakh by both BSE Limited and the National Stock Exchange of India Limited. Each exchange imposed a penalty of ₹65,000 on February 27, 2026, due to a non-compliance related to the completion of an Independent Director's term.
The company stated that the non-compliance arose because the term of an Independent Director concluded. Eris Lifesciences is actively screening candidates to fill the anticipated vacancy and expects to report compliance soon. The company emphasized its commitment to adhering to all applicable laws and regulations.
The financial impact of this penalty is limited to the total fine amount of ₹1.3 lakh. The company is taking steps to appoint a new Independent Director to rectify the composition of its Board of Directors.
What to do with a filing like this
Eris Lifesciences Limited filed this with the NSE as a statutory disclosure, categorised under other regulatory filings. It is a primary document, not a recommendation, and the desk marks it low impact, the band that almost never moves a portfolio on its own.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Eris Lifesciences Limited. Read the original for the full detail.